FROM PUBLIC EVENTS · 2026-11-18

Current stage

  1. Discovery · preclinical
  2. Early clinical · first deals
  3. Late clinical · capacity
  4. Commercial · sales
  1. Global approvals · expansion
  2. M&A · integration
  3. Pipeline reshaping

Pipeline reshaping After a large investment, it switched from sequential to parallel development of candidates and grew its team. Also seen: Discovery · preclinical

  • Unveiled three candidates and a parallel-development approach at its R&D Day. Source
  • Headcount grew from about 28 before the investment to 49. Source

Roles often seen at this stageResearch & development · BD & licensing

Companies at the same stage and their people flow →

← Company library
Korea / Company briefSources checked 2026-11-18

AprilBio

Founded in 2013, it develops antibody drugs for autoimmune and inflammatory diseases using its HuDVFab human antibody library and its half-life-extending SAFA platform.

APB-R3

Stage unconfirmed

A candidate for atopic dermatitis and other inflammatory diseases, licensed to Evommune in the US in 2024.

APB-A1

Stage unconfirmed

A candidate for thyroid eye disease and other autoimmune diseases, licensed to Lundbeck in 2021.

SAFA

Technology platform

Its in-house platform for extending the half-life of antibody fragments in the body.

Announced

Unveiled candidates for inflammatory bowel disease (APB-I-005), dyslipidemia (APB-O-001) and a cancer ADC (APB-A-001) at its R&D Day.

Official role guide

AprilBio careers

Current availability unconfirmed

Observed 2026-11-18

Work
Unconfirmed — The official careers page could not be confirmed.
Experience & requirements
Unconfirmed — The official careers page could not be confirmed.

Information from a role guide does not establish a current vacancy.

Sources & coverage 2

A brief based on selected official material, not an exhaustive product or vacancy list.

  1. "2027년 후보물질 3건 조기 기술이전"…에이프릴바이오, 투자금 활용해 사업 성과 앞당긴다 ↗MTN 머니투데이방송 · Published 2026-11-10 · Sources checked 2026-11-18 · Original unavailable
  2. 에이프릴바이오, 4300억 실탄으로 기술이전·도입 투트랙 ↗딜사이트 · Published 2026-11-09 · Sources checked 2026-11-18 · Original unavailable